6533b82cfe1ef96bd128eaa8

RESEARCH PRODUCT

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries

D A A M SchellingsM NeufangG CapturG CapturJ SchaapR S HermanidesC RiedelW L BorS G MazzilliJ L Van DoornJ P Van MeerbeeckM F L MeijsJ TrauthI. C. C. Van Der HorstE J MeijerA FriedrichsJ RedonC A BioléK HellwigE TessitoreF J F BroeyerBryan WilliamsBryan WilliamsC DegenhardtM CaputoGerry P MccannA MoriartyAzfar ZamanR M M GeversC E DelsingA G ErA J M Van BoxemE LensinkO V BlagovaD F MesitskayaR S PatelE SaneeiA N AlnafieN Y Y Al-windyMarijke LinschotenM Von Bergwelt-baildonE WierdaK JourdanAngela C. ShoreM TajdiniS E Van Der KooiR. Macias RuizS GrangeonA GucluAbdullah M. AlshehriA G M ZondagT VenemanL EberweinChiara Bucciarelli-ducciChiara Bucciarelli-ducciM BroekmanM. Van SmedenK WilleR M A Van De WalT E AllingP H M WestendorpA. Van LingenR PistersW R M HermansA AujayebK ElshinawyM MilovanovicA.g. RaafsE VliegheI C D WestendorpL E ZijlstraMichiel T H M HenkensB CosynsRobert M. BellA J MossJ A OfferhausK Van AkenA L GroenendijkI M J DrostM WormC P M Van NesR StraussC WeytjensM J G T VehreschildA MosterdD RauschningN C LeaJ M Kwakkel-van ErpS HandgraafM E EmansJ. De SutterH P A A Van VeenM G PerrelliN KnufmanS BorgmannH PoorhosseiniP WoudstraR J ThomsonR AhmedM AlshahraniJ T DrostF DormalL I VeldhuisD O VerschureF V Y TjongBas L.j.h. KietselaerM J FornerM BosA C ReidingaP MessiaenA M WillemsH BleijendaalD P RipleyJ.k. De VriesJ RüddelJ SeeligC BallE P A Van IperenS RiegM W J Van HessenN T B ScholteJ B FerreiraF S Van Den BrinkS E JansenP Den Boer-penningG L Ten KateB A S KooleS DolffC PiepelC SpinnerM KochanekM KochanekJ. M. Ten BergR SalahM Z H KolkA ShafieeN CharlotteP Van Der MeerB JensenJ SchubertM HowerA F M KuijperR A TioL Kuipers-elferinkL MontagnaP M Van Der ZeeD HeigenerLucia S.d. JewbaliN H SturkenboomM SaxenaR Byrom-goulthorpE A W De BruijnJ NattermannN A HaenenA M PersoonM BontjeM StecherFahad Al-muhannaC M KievitE HellouS ReindersA Van PoppelY A AlmubarakJ LanznasterP TimmermansP Van DoornLuis RomaoK HosseiniF HansesM BiancoC RömmeleStephane HeymansR L AnthonioF M A C MartensL TomettenJ. Vom DahlD J Van Der HeijdenL BoschP DarkC A Den UilA J MeleinA H RuiterP R NieropM MaarseN M CardosoH HeidbuchelM AlkhalilW GuggemosS K Zoet-nugterenA DunninkP KleikersM M RüthrichD LomasL PilgramJ T KielsteinS WilliamsB C T Van BusselA Pieterse-rotsJ DomangeS NadalinF M A ParisH A M Van KesterenE A BadingsC AnningE C E Bayraktar-ververJ HuismanM MagroS BruinsmaE.m. Van CraenenbroeckU MerleF J Bermúdez JiménesD H Van DalenL Tercedor SanchezM Van Der GraafM M J M Van Der LindenN IsbernerFolkert W. AsselbergsFolkert W. AsselbergsAmein K. Al-aliA. Van Der SluisE A Van BeekS H Van IersselH G R DormanR ZaalA M WilsYigal M. PintoI LemoineB C PölkermanV Van MarrewijkA HabibP C SmitsB E GroenemeijerM J ReitsmaE McfarlaneR G TielemanR G TielemanM Hendriks-van WoerdenJ L SelderL WalterAlicia UijlH J SiebelinkI VoigtGerard C.m. LinssenH VialMark T. KearneyD J Van De WateringH E VonkemanJ W M Van EckB GrünerD G GognievaP MarkartK HamiltonC E E Van Ofwegen-hanekampA JanssenC RaichleA I C SousaW. H. Van GilstB HedayatL GabrielS StieglitzK W WuP VreugdenhilK RothfussM A C KooleT WesthoffS PrasadC M Van De HeyningA M H KoningT A C De VriesA M Al-rubaishA D HiltE ParkerE DekimpeC E M JakobC E M JakobM I A RibeiroB M Hessels-linnemeijerP S MonraatsM J Van KempenW Hermans-van AstF J H MagdelijnsK K KuiH E Haerkens-arendsP Y KopylovA SchutT C JacobsP Van Der Harst

subject

medicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryDiseasemedicine.diseasesymbols.namesakeHeart failureInternal medicineRelative riskmedicinesymbolsPoisson regressionPresentation (obstetrics)businessCohort study

description

AbstractAimsPatients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and resultsWe used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and often had other comorbid conditions when compared to those without. Mortality was higher in patients with cardiac disease (29.7%; n=1545 versus 15.9%; n=1797). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.08 [95% CI 1.02 – 1.15; p-value 0.12 (corrected for multiple testing)]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure aRR (1.19 [1.10 – 1.30]; p-value <0.018) particularly for severe NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 – 1.64; p-value <0.018]. None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients.ConclusionConsiderable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare.

https://doi.org/10.1101/2021.03.11.21253106